| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Broadwood Believes the Transaction Comes at the Wrong Time, After the Wrong Process, and at the Wrong Price
For the Reasons Described in the Presentation, Broadwood Urges All Stockholders to Vote "AGAINST" the Proposed Merger
Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood"), holders of approximately 27.5% of the outstanding common stock of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today announced that it has published a presentation outlining why stockholders should vote on Broadwood's GREEN Proxy Card "AGAINST" the proposed acquisition of the Company by an affiliate of Alcon Inc. (NYSE:ALC) on the terms announced on August 5, 2025. The 81-page presentation is available here and on www.LetSTAARShine.com.
Neal Bradsher, President of Broadwood, stated:
"We believe that there was no compelling reason to sell STAAR at this time. Moreover, the Board of Directors failed to conduct a sale process in a responsible manner and ultimately agreed to a price that significantly undervalues STAAR and its bright future. Our presentation provides important new information regarding the deep flaws in this process and valuation.
I am pleased that two other notable stockholders have publicly opposed the transaction: Yunqi Capital Limited, which owns 5.1% of STAAR's common stock, and David Bailey, the former CEO of STAAR. Before making their voting decisions, all stockholders are encouraged to review our presentation, which describes why this transaction comes at the wrong time, after the wrong process, and at the wrong price."
